Loading
A phase 1/2 trial of Azacitidine and Venetoclax in acute myeloid leukaemia, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms and myelodysplastic syndromes / neoplasms, run by Faron Pharmaceuticals Ltd, active and no longer recruiting.
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies is a phase 1/2 interventional study registered as NCT05428969 by Faron Pharmaceuticals Ltd, with 181 participants enrolled, started 2022-06-02 and due to reach its primary completion in 2027-03. Interventions recorded: Bexmarilimab, Azacitidine and Venetoclax.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine, Venetoclax, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine, Venetoclax, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine, Venetoclax, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Azacitidine, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.